Cardiff Oncology, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cardiff Oncology, Inc. (CRDF) on June 16, 2020, covering events occurring on June 15, 2020. The filing primarily details a material definitive agreement for a capital raise and the announcement of clinical trial data for the company's oncology programs.
Key Financial Metrics and Capital Structure
The filing discloses a capital raise transaction with the following specific terms:
- Gross Proceeds: Approximately $13.5 million.
- Securities Issued:
- 1,984,328 shares of Common Stock (Registered Direct Offering).
- 865,824 shares of Series E Preferred Stock (Private Placement).
- Warrants to purchase up to 2,213,115 shares of Common Stock.
- Pricing: Combined purchase price of $2.44 per share (Common or Preferred) plus one Warrant.
- Warrant Terms: Exercise price of $2.39 per share; exercisable beginning six months after issuance for a five-year period.
- Preferred Stock Terms: $10 stated value per share; convertible at $2.44 per share; no liquidation preference; dividends paid on an as-if-converted basis.
The filing does not provide current revenue, profit, cash flow, or debt figures, as this is a current report focused on specific events rather than a periodic financial statement.
Material Changes and Clinical Developments
On June 15, 2020, the Company announced the presentation of clinical data at the European Hematology Association (EHA) annual conference:
- Phase 1b Study: Final results presented for relapsed or refractory acute myeloid leukemia (AML).
- Phase 2 Study: Preliminary positive data presented for the same indication.
Additionally, the Company filed a Certificate of Designation creating the Series E Preferred Stock, altering its capital structure to include this new equity class with specific voting protections for holders regarding adverse changes to their rights.
Outlook, Risks, and Contingencies
The closing of the securities offering is subject to the satisfaction of specified customary closing conditions. The Series E Preferred Stock includes an "Ownership Limitation," preventing purchasers from converting shares if it would result in beneficial ownership exceeding 9.99% of the outstanding Common Stock. The filing notes that the Preferred Shares, Conversion Shares, Warrants, and Warrant Shares were offered pursuant to exemptions under Section 4(a)(2) and Rule 506(b) of the Securities Act and are not registered.
Investor Verification Checklist
- Verify the final closing of the $13.5 million offering and the actual net proceeds after expenses.
- Review the full text of the press release (Exhibit 99.1) for detailed statistical outcomes of the Phase 1b and Phase 2 AML studies.
- Confirm the dilution impact of the 1,984,328 Common Shares and potential future conversion of 865,824 Series E Preferred Shares and 2,213,115 Warrant Shares.
- Monitor the exercise timeline for the Warrants, which begins six months post-issuance.